research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
Search
for
Sort by
Research
270-300 / 1000+ results
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Acute Bullous Dermatosis and Onycholysis due to High-Dose Methotrexate and Leucovorin Calcium
High-dose methotrexate can cause severe skin and nail issues.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review
Leflunomide can cause severe hair loss in some rheumatoid arthritis patients.
research New developments in the treatment of systemic lupus erythematosus
New treatments for lupus show promise, but more research is needed, especially for children.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss
A woman developed swelling in her body after taking low-dose oral minoxidil for hair loss, but it resolved after stopping the medication.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research SUN-174 Giant Bilateral Myelolipomas in a Patient with Congenital Adrenal Hyperplasia
A patient with untreated congenital adrenal hyperplasia had large benign tumors in her adrenal glands removed, improving her symptoms.
research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Case report: NUDT15 polymorphism and severe azathioprine-induced myelosuppression in a young Chinese female with systematic lupus erythematosus: a case analysis and literature review
Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research An unusual presentation of X-linked adrenoleukodystrophy
A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Drug Information Analysis Service
Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
research O-21 FROM ORAL LEVOTHYROXINE RESISTANCE TO INTRAVENOUS LEVOTHYROXINE HYPERSENSITIVITY: A CHALLENGING PRIMARY HYPOTHYROIDISM CASE
A woman with hypothyroidism developed an allergy to IV levothyroxine after being resistant to oral forms.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review
Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.